Original Articles

The Efficiency of Docetaxel Chemotherapy on Castration Resistant Prostate Cancer: Singe Center Experience

10.4274/uob.821

  • Evren Süer
  • Nurullah Hamidi
  • Mehmet Ilker Gökçe
  • Sümer Baltaci

Bull Urooncol 2017; 16 (3): 77-80 (Accepted Date: 31.05.2017) (Received Date: 06.02.2017)

Objective: Prostate cancer (PCa) is the second most commonly seen cancer type worldwide. Mortality due to PCa is mostly linked to the development of castration resistant PCa (CRPC). In these patients, the main treatment option is docetaxel based chemotherapy (DBC). In this study, we aimed to present our retrospective series. Materials and Methods: We retrospectively evaluated the patients who received DBC in our clinic between January 2004 and December 2015. Totally 162 patients who are histopathologically diagnosed with PCa, clinically and radiographically demonstrated metastasis and fit to European Association of Urology CRPC criteria were included to the study. DBC was given for one day for a 3-week period, with a dose of 75 mg/m2. Prostate specific antigen (PSA) response is evaluated for ≥50% decrease in the PSA level measured at the first day of the chemotherapy. Additionally, overall survival is evaluated. Results: The majority of the patients had high stage and high Gleason score PCa. Of them totally 76% were a primary metastatic. Two-year overall survival was 18.5%, median overall survival was 15.2 months in the study population. PSA response was demonstrated in 59.2% of the patients. In multivariate analysis, the CRPC development time was found to be an independent prognostic factor both for overall survival and PSA response. Conclusion: DBC is still the main treatment option for CRPC patients for long term and successful outcomes.

Keywords: Docetaxel, prognosis, prostate cancer, survival

Full Text (Turkish)